Medical Innovation
Americans today are benefiting from medical developments and discoveries that took shape almost two decades ago. On average, the travel time of an experimental drug from the lab to patients is 12 to15 years. Lawmakers need to realize the considerable impact that federal policies can have on maintaining the future of drug discovery and innovation.
All Americans, especially the aging, want the best therapies for life-threatening diseases and disabling and chronic conditions. A core goal of the Alliance for Aging Research is to encourage policies which will lead to newer and better treatments to improve the health and independence of Americans as they age.
Related Publications
-
DocumentThe Burden and Future Implications of
Adult Visual Disorders in the United States
In an Alliance for Aging Research, National Alliance for Eye and Vision Research (NAEVR) joint briefing, David Rein, PhD, presented on the current economic burden of vision loss and the potential future impact. His slides are available here. -
DocumentAge-Related Maculopathy:
What it is, what we know, what we need to learn
In an Alliance for Aging Research, National Alliance for Eye and Vision Research (NAEVR briefing, Dr. Michael Gorin presented on age-related maculopathy, an eye disease that affects millions of Americans. His presentation slides are available here. -
DocumentFuture Perspectives on Diabetes: What can we do for seniors?
In the last of four briefings looking at the growing burden of chronic disease and the promise of medical innovation, Dr. William Rowley of The Institute for Alternative Futures, presented on Future Perspectives of Diabetes. His presentation slides are available here.
